Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Profit After Tax: 2013-2025

Historic Profit After Tax for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $17.4 million.

  • Amphastar Pharmaceuticals' Profit After Tax fell 57.09% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year decrease of 29.22%. This contributed to the annual value of $159.5 million for FY2024, which is 15.98% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Profit After Tax of $17.4 million as of Q3 2025, which was down 44.09% from $31.0 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Profit After Tax peaked at $49.2 million during Q3 2023, and registered a low of $5.0 million during Q1 2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Profit After Tax value was $36.2 million (recorded in 2023), while the average stood at $33.7 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first surged by 703.36% in 2021, then plummeted by 57.09% in 2025.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Profit After Tax stood at $19.8 million in 2021, then skyrocketed by 71.62% to $33.9 million in 2022, then grew by 6.65% to $36.2 million in 2023, then grew by 4.97% to $38.0 million in 2024, then plummeted by 57.09% to $17.4 million in 2025.
  • Its Profit After Tax was $17.4 million in Q3 2025, compared to $31.0 million in Q2 2025 and $25.3 million in Q1 2025.